Sulfonyl-substituted bicyclic compounds as modulators of PPAR
Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.
1. 4-[2,6-Dimethyl-4-(4-trifluoromethoxy-benzyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid.
2. 4-[cis-2,6-Dimethyl-4-(4-trifluoromethoxy-benzyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid.
3. A single enantiomer of 4-[cis-2,6-dimethyl-4-(4-trifluoromethoxy-benzyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid substantially free of the other enantiomer.
4. A pharmaceutically acceptable salt of 4-[cis-2,6-dimethyl-4-(4-trifluoromethoxy-benzyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid.
5. A pharmaceutical composition comprising at least one compound having the formula of
or a salt thereof; and
a pharmaceutically acceptable carrier.
6. A pharmaceutical composition for treating diabetes comprising an antidiabetic effective amount of a compound of claim 1 and together with a pharmaceutically acceptable carrier.
7. A pharmaceutical composition comprising a compound as recited in claim 1 together with a pharmaceutically acceptable carrier.
8. A pharmaceutical composition comprising a compound as recited in claim 2 together with a pharmaceutically acceptable carrier.
9. A pharmaceutical composition comprising a compound as recited in claim 3 together with a pharmaceutically acceptable carrier.
10. A pharmaceutical composition comprising a compound as recited in claim 4 together with a pharmaceutically acceptable carrier.